RU2738803C2 - Композиция и способ лечения и профилактики кишечной инфекции и воспаления - Google Patents
Композиция и способ лечения и профилактики кишечной инфекции и воспаления Download PDFInfo
- Publication number
- RU2738803C2 RU2738803C2 RU2018105964A RU2018105964A RU2738803C2 RU 2738803 C2 RU2738803 C2 RU 2738803C2 RU 2018105964 A RU2018105964 A RU 2018105964A RU 2018105964 A RU2018105964 A RU 2018105964A RU 2738803 C2 RU2738803 C2 RU 2738803C2
- Authority
- RU
- Russia
- Prior art keywords
- lmg
- composition
- plantarum
- fiber
- strains
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 185
- 230000004054 inflammatory process Effects 0.000 title claims description 10
- 206010061218 Inflammation Diseases 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 32
- 206010022678 Intestinal infections Diseases 0.000 title description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 188
- 241000186660 Lactobacillus Species 0.000 claims abstract description 79
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 72
- 241000186869 Lactobacillus salivarius Species 0.000 claims abstract description 71
- 240000001929 Lactobacillus brevis Species 0.000 claims abstract description 64
- 101100342487 Oryza sativa subsp. indica KSL11 gene Proteins 0.000 claims abstract description 64
- 208000010643 digestive system disease Diseases 0.000 claims abstract description 62
- 208000018685 gastrointestinal system disease Diseases 0.000 claims abstract description 62
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 26
- 230000001332 colony forming effect Effects 0.000 claims abstract description 4
- 238000011282 treatment Methods 0.000 claims description 68
- 241000193163 Clostridioides difficile Species 0.000 claims description 62
- 239000000835 fiber Substances 0.000 claims description 55
- 241000894006 Bacteria Species 0.000 claims description 46
- 230000002265 prevention Effects 0.000 claims description 45
- 208000015181 infectious disease Diseases 0.000 claims description 29
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 29
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 claims description 26
- 108090001007 Interleukin-8 Proteins 0.000 claims description 26
- 241000792859 Enema Species 0.000 claims description 22
- 239000007920 enema Substances 0.000 claims description 22
- 229940095399 enema Drugs 0.000 claims description 21
- 206010012735 Diarrhoea Diseases 0.000 claims description 20
- 241000588724 Escherichia coli Species 0.000 claims description 18
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 18
- 241000607142 Salmonella Species 0.000 claims description 17
- 235000021395 porridge Nutrition 0.000 claims description 17
- 208000005577 Gastroenteritis Diseases 0.000 claims description 15
- 208000035143 Bacterial infection Diseases 0.000 claims description 10
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 10
- 206010012742 Diarrhoea infectious Diseases 0.000 claims description 8
- 206010000059 abdominal discomfort Diseases 0.000 claims description 8
- 208000001848 dysentery Diseases 0.000 claims description 8
- 238000001802 infusion Methods 0.000 claims description 8
- 235000011962 puddings Nutrition 0.000 claims description 8
- 239000002002 slurry Substances 0.000 claims description 7
- 240000008042 Zea mays Species 0.000 claims description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 6
- 208000012873 acute gastroenteritis Diseases 0.000 claims description 6
- 235000005822 corn Nutrition 0.000 claims description 6
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims description 6
- 240000005979 Hordeum vulgare Species 0.000 claims description 5
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 5
- 241000209140 Triticum Species 0.000 claims description 5
- 235000021307 Triticum Nutrition 0.000 claims description 5
- 235000013339 cereals Nutrition 0.000 claims description 5
- 235000013311 vegetables Nutrition 0.000 claims description 5
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 claims description 4
- 240000005481 Salvia hispanica Species 0.000 claims description 4
- 235000001498 Salvia hispanica Nutrition 0.000 claims description 4
- 244000061456 Solanum tuberosum Species 0.000 claims description 4
- 235000002595 Solanum tuberosum Nutrition 0.000 claims description 4
- 235000014167 chia Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 235000019895 oat fiber Nutrition 0.000 claims description 4
- 239000003814 drug Substances 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 25
- 230000008901 benefit Effects 0.000 description 21
- 230000012010 growth Effects 0.000 description 20
- 239000007788 liquid Substances 0.000 description 20
- 230000005764 inhibitory process Effects 0.000 description 16
- 239000002609 medium Substances 0.000 description 16
- 210000003289 regulatory T cell Anatomy 0.000 description 14
- 210000001035 gastrointestinal tract Anatomy 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 11
- 239000003242 anti bacterial agent Substances 0.000 description 11
- 229940072205 lactobacillus plantarum Drugs 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 230000003115 biocidal effect Effects 0.000 description 10
- 241000736262 Microbiota Species 0.000 description 9
- 108010059993 Vancomycin Proteins 0.000 description 9
- 229960000282 metronidazole Drugs 0.000 description 9
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229960003165 vancomycin Drugs 0.000 description 9
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 9
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000002865 immune cell Anatomy 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- 230000002550 fecal effect Effects 0.000 description 7
- 244000005709 gut microbiome Species 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 230000000069 prophylactic effect Effects 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 6
- 241000186605 Lactobacillus paracasei Species 0.000 description 6
- 241000917009 Lactobacillus rhamnosus GG Species 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 5
- 241000607768 Shigella Species 0.000 description 5
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 230000003042 antagnostic effect Effects 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000035945 sensitivity Effects 0.000 description 5
- 230000035899 viability Effects 0.000 description 5
- 206010058838 Enterocolitis infectious Diseases 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 241000607734 Yersinia <bacteria> Species 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000845 anti-microbial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000003608 fece Anatomy 0.000 description 4
- 208000009326 ileitis Diseases 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000027139 infectious colitis Diseases 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000005027 intestinal barrier Anatomy 0.000 description 4
- 230000007358 intestinal barrier function Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 210000003563 lymphoid tissue Anatomy 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 230000000529 probiotic effect Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000193755 Bacillus cereus Species 0.000 description 3
- 206010009900 Colitis ulcerative Diseases 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 3
- 241000191940 Staphylococcus Species 0.000 description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 3
- 235000021186 dishes Nutrition 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000000306 recurrent effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000589876 Campylobacter Species 0.000 description 2
- 241001112696 Clostridia Species 0.000 description 2
- 208000037384 Clostridium Infections Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010017964 Gastrointestinal infection Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 238000002768 Kirby-Bauer method Methods 0.000 description 2
- 241000186781 Listeria Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000012868 Overgrowth Diseases 0.000 description 2
- 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 description 2
- 206010037128 Pseudomembranous colitis Diseases 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241000194024 Streptococcus salivarius Species 0.000 description 2
- 241000607598 Vibrio Species 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012736 aqueous medium Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000006161 blood agar Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 230000000741 diarrhetic effect Effects 0.000 description 2
- 208000019836 digestive system infectious disease Diseases 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000004609 intestinal homeostasis Effects 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 210000000110 microvilli Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- PFFIDZXUXFLSSR-UHFFFAOYSA-N 1-methyl-N-[2-(4-methylpentan-2-yl)-3-thienyl]-3-(trifluoromethyl)pyrazole-4-carboxamide Chemical compound S1C=CC(NC(=O)C=2C(=NN(C)C=2)C(F)(F)F)=C1C(C)CC(C)C PFFIDZXUXFLSSR-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000032862 Clinical Deterioration Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 241000758791 Juglandaceae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000003805 Musa ABB Group Nutrition 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 235000015266 Plantago major Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 244000134857 Typha capensis Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 241000607447 Yersinia enterocolitica Species 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000010065 bacterial adhesion Effects 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- MYPYJXKWCTUITO-KIIOPKALSA-N chembl3301825 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)C(O)[C@H](C)O1 MYPYJXKWCTUITO-KIIOPKALSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 229940004552 dificid Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000029036 donor selection Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 208000010227 enterocolitis Diseases 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- ZVGNESXIJDCBKN-UUEYKCAUSA-N fidaxomicin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@H]([C@H]1O)OC)OCC\1=C/C=C/C[C@H](O)/C(C)=C/[C@@H]([C@H](/C(C)=C/C(/C)=C/C[C@H](OC/1=O)[C@@H](C)O)O[C@H]1[C@H]([C@@H](O)[C@H](OC(=O)C(C)C)C(C)(C)O1)O)CC)C(=O)C1=C(O)C(Cl)=C(O)C(Cl)=C1CC ZVGNESXIJDCBKN-UUEYKCAUSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 244000000036 gastrointestinal pathogen Species 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000036433 growing body Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 244000000074 intestinal pathogen Species 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 235000013575 mashed potatoes Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000021049 nutrient content Nutrition 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 210000001986 peyer's patch Anatomy 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108020004418 ribosomal RNA Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE1551099 | 2015-08-25 | ||
| SE1551099-3 | 2015-08-25 | ||
| PCT/SE2016/050787 WO2017034460A1 (en) | 2015-08-25 | 2016-08-23 | Composition and method for treatment and prophylaxis of intestinal infection and inflammation |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2018105964A RU2018105964A (ru) | 2019-09-26 |
| RU2018105964A3 RU2018105964A3 (enExample) | 2020-01-28 |
| RU2738803C2 true RU2738803C2 (ru) | 2020-12-17 |
Family
ID=58100550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018105964A RU2738803C2 (ru) | 2015-08-25 | 2016-08-23 | Композиция и способ лечения и профилактики кишечной инфекции и воспаления |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10632159B2 (enExample) |
| EP (1) | EP3341001B1 (enExample) |
| JP (1) | JP6957452B2 (enExample) |
| KR (1) | KR102656709B1 (enExample) |
| CN (1) | CN108135948B (enExample) |
| AU (2) | AU2016312870B2 (enExample) |
| BR (1) | BR112018003123B1 (enExample) |
| CA (1) | CA2995071A1 (enExample) |
| DK (1) | DK3341001T3 (enExample) |
| ES (1) | ES2909430T3 (enExample) |
| IL (1) | IL257568A (enExample) |
| MX (1) | MX395262B (enExample) |
| PL (1) | PL3341001T3 (enExample) |
| RU (1) | RU2738803C2 (enExample) |
| WO (1) | WO2017034460A1 (enExample) |
| ZA (1) | ZA201801266B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7015674B2 (ja) * | 2017-10-27 | 2022-02-15 | 日清食品ホールディングス株式会社 | 制御性ｔ細胞の分化誘導剤及び分化誘導方法 |
| JP2019187251A (ja) * | 2018-04-19 | 2019-10-31 | 国立研究開発法人農業・食品産業技術総合研究機構 | 発酵物の製造方法及び発酵物 |
| WO2020180037A1 (ko) * | 2019-03-04 | 2020-09-10 | 경북대학교 산학협력단 | 인간 장내 미생물 군집 모사 배양용 조성물, 혐기 배양 체계를 이용한 인간 장내 미생물 군집의 모사 배양 방법, 이에 의해 제조된 미생물 제제 및 이의 용도 |
| CN110129221B (zh) * | 2019-05-06 | 2022-05-17 | 福建晋江国食文化传媒有限公司 | 乳酸菌hwn19菌株及其应用 |
| CN111358798A (zh) * | 2020-03-13 | 2020-07-03 | 暨南大学 | 低聚糖阿魏酸酯的新应用 |
| WO2022039561A1 (ko) * | 2020-08-21 | 2022-02-24 | 서울대학교산학협력단 | 클로스트리디움 디피실리 감염의 치료 또는 예방용 조성물 |
| KR102488609B1 (ko) * | 2020-09-24 | 2023-01-12 | 국립낙동강생물자원관 | 장내 유해세균 억제 기능을 가진 락토바실러스 파라부크네리 nsmj16 (kacc81129bp) 및 락토바실러스 브레비스 nsmj23(kacc81130bp) |
| KR102363975B1 (ko) * | 2020-12-11 | 2022-02-17 | 주식회사 바이오뱅크힐링 | 락토바실러스 플란타룸 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN112625983B (zh) * | 2021-03-05 | 2021-05-28 | 山东中科嘉亿生物工程有限公司 | 一种对腹泻有治疗效果的干酪乳杆菌L.Casei21及其应用 |
| US12433922B2 (en) * | 2021-09-22 | 2025-10-07 | Asahi Biocycle Co., Ltd. | Composition for prophylaxis of enteritis in avian comprising lactobacillus plantarum strain |
| CN115466699B (zh) * | 2022-09-28 | 2023-03-31 | 成都大熊猫繁育研究基地 | 熊猫源唾液乳杆菌及在治疗或预防炎症性肠病中的应用 |
| CN116286476B (zh) * | 2023-02-06 | 2025-09-12 | 华南理工大学 | 一株短乳杆菌及其抑菌优化培养方法和应用 |
| CN116875520B (zh) * | 2023-07-12 | 2024-06-14 | 吉林农业大学 | 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用 |
| KR102628942B1 (ko) * | 2023-08-08 | 2024-01-26 | 주식회사 바이오뱅크힐링 | 레비락토바실러스 브레비스 균주, 및 그의 유래의 소포체및 그의 항염증 및 항균 용도 |
| WO2025033636A1 (ko) * | 2023-08-08 | 2025-02-13 | 주식회사 바이오뱅크힐링 | 신규 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도 |
| CN117467568B (zh) * | 2023-09-22 | 2025-02-14 | 福建省农业科学院畜牧兽医研究所 | 一株短乳杆菌zg-7及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008064521A1 (en) * | 2006-11-30 | 2008-06-05 | Pharmapep Research & Development (Shenzhen) Co., Ltd. | Lactobacillus fermentum cms-h002 and use thereof |
| WO2009047537A1 (en) * | 2007-10-11 | 2009-04-16 | Fayrefield Foods Limited | Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1306716B1 (it) * | 1999-06-21 | 2001-10-02 | Mendes S U R L | Associazione di batteri lattici e suo uso per la prevenzione e/o iltrattamento terapeutico di infezioni e di stati infiammatori. |
| PE20030274A1 (es) * | 2001-07-26 | 2003-05-08 | Alimentary Health Ltd | Cepas de lactobacillus salivarius |
| JP5363811B2 (ja) * | 2005-09-28 | 2013-12-11 | ノルディスク リバランス アクティーゼルスカブ | 治療エフェクターとしてプロバイオティック細菌と発酵穀物を用いるｉｂｄ及びｉｂｓの治療 |
| WO2012142605A1 (en) * | 2011-04-15 | 2012-10-18 | Samaritan Health Services | Rapid recolonization deployment agent |
| US9579353B2 (en) * | 2011-06-10 | 2017-02-28 | Prothera, Inc. | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
| JP2014166972A (ja) * | 2013-02-28 | 2014-09-11 | Kagome Co Ltd | 腸炎抑制剤及び飲食品 |
| CN104611275B (zh) * | 2015-02-11 | 2017-10-17 | 成都与康科技有限公司 | 植物乳杆菌ucn‑11菌株及其组合物和应用 |
-
2016
- 2016-08-23 CN CN201680049055.9A patent/CN108135948B/zh active Active
- 2016-08-23 PL PL16839703T patent/PL3341001T3/pl unknown
- 2016-08-23 KR KR1020187005513A patent/KR102656709B1/ko active Active
- 2016-08-23 EP EP16839703.2A patent/EP3341001B1/en active Active
- 2016-08-23 DK DK16839703.2T patent/DK3341001T3/da active
- 2016-08-23 ES ES16839703T patent/ES2909430T3/es active Active
- 2016-08-23 AU AU2016312870A patent/AU2016312870B2/en active Active
- 2016-08-23 WO PCT/SE2016/050787 patent/WO2017034460A1/en not_active Ceased
- 2016-08-23 MX MX2018002093A patent/MX395262B/es unknown
- 2016-08-23 US US15/753,692 patent/US10632159B2/en active Active
- 2016-08-23 RU RU2018105964A patent/RU2738803C2/ru active
- 2016-08-23 BR BR112018003123-2A patent/BR112018003123B1/pt active IP Right Grant
- 2016-08-23 JP JP2018510510A patent/JP6957452B2/ja active Active
- 2016-08-23 CA CA2995071A patent/CA2995071A1/en active Pending
-
2018
- 2018-02-16 IL IL257568A patent/IL257568A/en unknown
- 2018-02-23 ZA ZA2018/01266A patent/ZA201801266B/en unknown
-
2023
- 2023-03-31 AU AU2023201997A patent/AU2023201997A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008064521A1 (en) * | 2006-11-30 | 2008-06-05 | Pharmapep Research & Development (Shenzhen) Co., Ltd. | Lactobacillus fermentum cms-h002 and use thereof |
| WO2009047537A1 (en) * | 2007-10-11 | 2009-04-16 | Fayrefield Foods Limited | Preparation for treating intestinal infection comprising oligosaccharides and insoluble cellular material |
Non-Patent Citations (2)
| Title |
|---|
| HELL M. ET AL. Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Benef Microbes. 2013 Mar 1;4(1):39-51. IANNITTI T. ET AL. Therapeutical use of probiotic formulations in clinical practice. Clin Nutr. 2010 Dec;29(6):701-25. * |
| ШЕНДЕРОВ Б.А. Медицинская микробная экология и функциональное питание. Том III: Пробиотики и функциональное питание. - М.: Издательство "ГРАНТЪ", 2001, с. 85. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018105964A3 (enExample) | 2020-01-28 |
| MX2018002093A (es) | 2018-09-12 |
| PL3341001T3 (pl) | 2022-07-04 |
| US20180243353A1 (en) | 2018-08-30 |
| JP6957452B2 (ja) | 2021-11-02 |
| AU2023201997A1 (en) | 2023-05-04 |
| AU2016312870A1 (en) | 2018-03-08 |
| BR112018003123B1 (pt) | 2021-09-28 |
| ES2909430T3 (es) | 2022-05-06 |
| EP3341001B1 (en) | 2021-12-29 |
| ZA201801266B (en) | 2019-06-26 |
| CN108135948A (zh) | 2018-06-08 |
| CN108135948B (zh) | 2022-04-12 |
| RU2018105964A (ru) | 2019-09-26 |
| BR112018003123A2 (pt) | 2018-09-25 |
| EP3341001A4 (en) | 2019-07-03 |
| KR20180041144A (ko) | 2018-04-23 |
| CA2995071A1 (en) | 2017-03-02 |
| DK3341001T3 (da) | 2022-03-21 |
| MX395262B (es) | 2025-03-25 |
| EP3341001A1 (en) | 2018-07-04 |
| WO2017034460A1 (en) | 2017-03-02 |
| IL257568A (en) | 2018-04-30 |
| US10632159B2 (en) | 2020-04-28 |
| KR102656709B1 (ko) | 2024-04-09 |
| JP2018526370A (ja) | 2018-09-13 |
| AU2016312870B2 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2738803C2 (ru) | Композиция и способ лечения и профилактики кишечной инфекции и воспаления | |
| JP7266636B2 (ja) | 食物アレルギーの処置および／または防止のための治療用微生物叢 | |
| JP7168558B2 (ja) | Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置 | |
| Jiang et al. | Evaluation of probiotic properties of Lactobacillus plantarum WLPL04 isolated from human breast milk | |
| JP2024129008A (ja) | 相乗的細菌組成物並びにその生成及び使用の方法 | |
| You et al. | Evidence of immunomodulatory effects of a novel probiotic, Bifidobacterium longum bv. infantis CCUG 52486 | |
| MXPA04000738A (es) | Cepas de bifidobacterium probiotico. | |
| JP2002534113A (ja) | 炎症性疾患治療におけるビフィドバクテリウム（Ｂｉｆｉｄｏｂａｃｔｅｒｉｕｍ） | |
| Mansour et al. | Inhibition of Clostridium difficile in mice using a mixture of potential probiotic strains Enterococcus faecalis NM815, E. faecalis NM915, and E. faecium NM1015: novel candidates to control C. difficile infection (CDI) | |
| Marx | Immunoprotective effects of probiotics in the elderly | |
| KR101488770B1 (ko) | 한국 장수마을의 장수인에게서 개발한 락토바실러스 퍼멘텀 ｐｌ９０３６ | |
| JP2006180836A (ja) | 食中毒菌感染を抑制する乳酸菌、ならびにそれを含む発酵物、食品および医薬組成物 | |
| WO2021081362A1 (en) | Synbiotic compositions for gut microbiota | |
| Pande et al. | Prospectus of probiotics in modern age diseases | |
| Gupta et al. | Synbiotics: promoting gastrointestinal health | |
| Wibowo et al. | The status of probiotics supplementation during pregnancy | |
| Hadid | Evaluating the Effects of Probiotics and Vinegars on Bacteria Isolated from Burns and Wounds Infections | |
| Fiore | Overall Assessment of a Model Probiotic Bacterium: from Gut Colonization to Clinical Efficacy | |
| ATALAY | THE USE OF PROBIOTICS IN GASTROINTESTINAL DISEASES | |
| Wang | Comparison of Microbial Quality of Commercial Probiotic Dietary Supplements | |
| TW202417026A (zh) | 益生菌組合及其用於腸胃道保健或提升免疫力的用途 | |
| Kumar et al. | Probiotics: Interactions with gut microbiota and emerging trends | |
| GS | Comparative Evaluation of the Efficacy of the Probiotic, Chlorhexidineand Fluoride Mouthwash Against Salivary Streptococcus Mutans-An in Vivo Study | |
| Gianotti et al. | Role of probiotics in colorectal surgery: a prospective randomized double-blind pilot study. | |
| Braun | Antibiotics and probiotics: the evidence |